Newsfeeds - Spark Newswire

1 minute read

Earnings

Earnings Outlook For Retrophin

Today, 2:41 PM

Retrophin (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Retrophin will report an earnings per share (EPS) of $-0.85.

TVTX

1 minute read

Travere Therapeutics To Present Abstracts At The Society For Inherited Metabolic Disorders 43rd Annual Meeting And The Genetic Metabolic Dieticians International Conference 2022 April 10-13 And May 4-7

By Benzinga Newsdesk

Today, 2:41 PM

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the Company will present data from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase, a novel investigational enzyme replacement therapy being evaluated

TVTX

1 minute read

Travere Therapeutics Submits New Drug Application For Sparsentan For The Treatment Of IgA Nephropathy

By Benzinga Newsdesk

Today, 2:41 PM

Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) under Subpart H for accelerated approval of sparsentan for the

TVTX

1 minute read

HC Wainwright & Co. Initiates Coverage On Travere Therapeutics with Buy Rating, Announces Price Target of $45

By Benzinga Newsdesk

Today, 2:41 PM

HC Wainwright & Co. analyst Ed Arce initiates coverage on Travere Therapeutics (NASDAQ:TVTX) with a Buy rating and announces Price Target of $45.

TVTX

1 minute read

Earnings

Travere Therapeutics: Q4 Earnings Insights

By Benzinga Insights

Today, 2:41 PM

Travere Therapeutics (NASDAQ:TVTX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

TVTX

1 minute read

Earnings

Travere Therapeutics’s Earnings: A Preview

By Benzinga Insights

Today, 2:41 PM

Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts estimate that Travere Therapeutics will report an earnings per share (EPS) of $-0.72.

TVTX

4 minute read

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

By Shanthi Rexaline

Today, 2:41 PM

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

ABCL

2 minute read

Travere Therapeutics 8-K Shows Co. Commercial Supply Deal With Catalent Pharma Solutions For Services Related To Processing, Packaging Of Sparsentan Tablets, No Terms Disclosed

By Benzinga Newsdesk

Today, 2:41 PM

On December 21, 2021, Travere Therapeutics, Inc. (the “Company”) entered into a Commercial Supply Agreement (the “Supply Agreement”) with Catalent Pharma Solutions, LLC (“Catalent”),

TVTX